Oral naltrexone can reduce health care costs

Apr 05, 2010

Alcohol-use disorders (AUDs), referring to both alcohol abuse and alcohol dependence, affect nearly 8.5 percent of the American population, are associated with numerous medical, psychiatric, family, legal, and work-related problems, and cost an estimated $185 billion in 1998. A new study has found that oral naltrexone can reduce both alcohol- and non-alcohol-related healthcare costs for patients with AUDs.

Results will be published in the June 2010 issue of Alcoholism: Clinical & Experimental Research and are currently available at Early View.

"Oral was approved by the Food and Drug Administration in 1994," explained Henry R. Kranzler, a professor in the department of psychiatry at the University of Connecticut Health Center and corresponding author for the study. "It was the first medication approved to treat dependence since disulfiram was approved in 1949, and its approval was based on a demonstration of efficacy using a randomized, controlled trial design. The FDA has since approved acamprosate and long-acting naltrexone." Kranzler believes that oral naltrexone is covered by most health plans as a generic drug.

For this study, Kranzler and his colleagues used data from the MarketScan Commercial Claims and Encounters Database for 2000 to 2004 to create three groups: a naltrexone group (n=1,138) with an alcohol-related diagnosis and at least one pharmacy claim for oral naltrexone; an alcohol control group (n=3,411) with an alcohol-related diagnosis but no prescription for alcoholism-treatment medication; and a non-alcohol control group (n=3,410) with no alcohol-related diagnosis and no prescription for alcoholism-treatment medication. The two groups with an alcohol-related diagnosis were matched to each other on a variety of demographic and clinical dimensions. Healthcare expenditures were calculated for the six-month periods before and after naltrexone drug claims, and dates were matched for the two control groups.

"We found that, prior to the start of the study period, individuals treated with naltrexone had higher healthcare costs than the group with an alcohol-related diagnosis but no naltrexone treatment," said Kranzler. "However, during the period after receiving the medication, the naltrexone group showed a significantly smaller increase in healthcare expenditures (both alcohol-related and non-alcohol-related) than the group with an alcohol-related diagnosis but no naltrexone treatment." In other words, oral naltrexone seemed to reduce healthcare costs for patients with an alcohol-related diagnosis.

Kranzler said these findings have implications for two groups. "I think that the greatest applications of these results are for healthcare policy makers, treatment-program managers, insurance companies, and health-benefits managers," he said. "They also show researchers that developments in treatment can pay dividends in cost savings."

Furthermore, he added, this study shows there is a common ground between effective treatment measures and cost-savings. "As a physician, I am interested in all treatments that can alleviate suffering and improve people's lives, however, I am also cognizant of the need to contain healthcare costs. This study suggests that an alcoholism treatment medication can help to contain healthcare costs and that wider consideration of the economic value of such approaches is warranted."

Explore further: Cold cash just keeps washing in from ALS challenge

Provided by Alcoholism: Clinical & Experimental Research

4 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

Naltrexone can help heavy social drinkers quit smoking

Mar 19, 2009

Naltrexone, an opioid antagonist approved in 1994 by the U.S. Food and Drug Administration for alcohol-dependence (AD) treatment, can reduce relapse rates among AD patients. Research on naltrexone's effectiveness on nicotine ...

Treating alcohol-use disorders and tuberculosis together

Nov 19, 2009

The integration of alcohol screening, treatment and referral into primary care and other medical settings is not routinely done. Nor are there any studies evaluating the effectiveness of integrating care for alcohol use ...

Recommended for you

Cold cash just keeps washing in from ALS challenge

Aug 28, 2014

In the couple of hours it took an official from the ALS Association to return a reporter's call for comment, the group's ubiquitous "ice bucket challenge" had brought in a few million more dollars.

Medtronic spends $350M on another European deal

Aug 27, 2014

U.S. medical device maker Medtronic is building stronger ties to Europe, a couple months after announcing a $42.9 billion acquisition that involves moving its main executive offices across the Atlantic, where it can get a ...

Mind over matter for people with disabilities

Aug 26, 2014

People with serious physical disabilities are unable to do the everyday things that most of us take for granted despite having the will – and the brainpower – to do so. This is changing thanks to European ...

Ukraine's former world's tallest man dies

Aug 25, 2014

Ukraine's tallest man, who briefly held the world record but gave it up to live as a recluse, has died due to complications from the condition that saw him never stop growing, local media reported Monday.

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

1 / 5 (1) Apr 05, 2010
Low dose naltrexone (3 to 4.5 mg/day either oral or topical) is very effective in combating; MS, rheumatoid arthritis, Crohn's disease and other intestinal disorders, and a variety of other illnesses. One has to chase down their own information about this orphan drug since wide spread use would significantly reduce health care costs and thus the Industrial Medical Complex's profits.